^
    2d
    A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 (clinicaltrials.gov)
    P2, N=316, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2027 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    2d
    ARTEMIDE-subQ: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca
    Trial initiation date
    |
    rilvegostomig (AZD2936)
    3d
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=56, Recruiting, AstraZeneca | N=43 --> 56
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    10d
    D702KC00001: A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) (2024-519786-22-01)
    P1/2, N=43, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)
    11d
    Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Diwakar Davar | Recruiting --> Active, not recruiting | N=26 --> 8 | Trial completion date: Jan 2031 --> Jan 2030 | Trial primary completion date: Jan 2028 --> Feb 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    BRAF mutation
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    13d
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=186, Recruiting, AstraZeneca | N=89 --> 186
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    17d
    D702NC00001: A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy in adults with advanced biliary tract cancer (2025-523085-24-00)
    P2/3, N=89, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    18d
    ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=212, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    rilvegostomig (AZD2936)
    19d
    INDIGO: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gustave Roussy, Cancer Campus, Grand Paris | N=115 --> 0 | Trial completion date: Jan 2030 --> Sep 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2028 --> Sep 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    24d
    GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=163, Recruiting, AstraZeneca | N=240 --> 163 | Trial completion date: Sep 2027 --> May 2029 | Trial primary completion date: Jul 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    24d
    KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=49, Completed, Merck Sharp & Dohme LLC | N=37 --> 49
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    25d
    ARTEMIDE-subQ: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca
    Trial initiation date
    |
    rilvegostomig (AZD2936)